BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 4, 2019
View Archived Issues
Fibroblasts specialize, too
Read More
Cracking influenza's egg code
Read More
CCR5 mutation leads to increased mortality
Read More
ECI-006 vaccine demonstrates promising safety and immunogenicity in patients with melanoma
Read More
First-in-human results presented for FPA-150 in patients with advanced solid tumors
Read More
MYLK genetic variant is associated with risk of pulmonary hypertension in sickle cell disease
Read More
Dosing initiated in phase I study of XmAb-22841 bispecific antibody
Read More
First patient dosed in phase III PEACE study of pegzilarginase in arginase 1 deficiency
Read More
BioInvent seeks IND clearance for phase I/IIa study of anti-FcgammaRllB antibody
Read More
Chinese researchers patent PI3K inhibitors
Read More
WntRx Pharmaceuticals identifies Wnt signaling inhibitors
Read More
Conditional European marketing authorization for Zynteglo for transfusion-dependent beta-thalassemia
Read More
Kissei Pharmaceutical describes CGRP receptor antagonists
Read More
Polish researchers identify 5-HT6 receptor antagonists
Read More
Jeil Pharmaceutical divulges new H+/K+-ATPase inhibitors
Read More
Kyowa Hakko Kirin initiates Japanese phase III trial of brodalumab in systemic sclerosis
Read More
Oligomerix continues NIH-funded work on tau oligomer inhibitor
Read More
First clinical data for Daiichi's IDH inhibitor DS-1001 presented for recurrent glioma
Read More
Phase III BLOCKSTONE study of Xofluza to prevent influenza infection meets primary endpoint
Read More
Qurient reports phase IIa data on telacebec for TB
Read More
FDA clears Nouscom's IND for phase I trial of NOUS-209 in MSI solid tumors
Read More
CEPI provides funding to support Themis' development of chikungunya vaccine MK-CHIK
Read More
Phase II trial of MD-7246 for IBS-D abdominal pain begins dosing
Read More
FDA approves Zerbaxa for hospital-acquired and ventilator-associated bacterial pneumonia
Read More